Search clinical trials for: rituximab [MabThera]

Total 3111 results

First Affiliated Hospital, Sun Yat-Sen University

Recruiting

Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy

Primary Membranous Nephropathy

China
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

MALT Lymphoma

Switzerland, Italy, France
National Cancer Institute (NCI)

Active, not recruiting

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Ann Arbor Stage III Non-Hodgkin Lymphoma | Ann Arbor Stage IV Non-Hodgkin Lymphoma | Ann Arbor Stage II Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Suspended

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

United States
Wake Forest University Health Sciences

Completed

Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases

Multiple Sclerosis

United States
M.D. Anderson Cancer Center

Terminated

Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System

Leukemia | Metastatic Malignant Neoplasm to the Leptomeninges | Lymphoid Malignancies

United States
University of California, San Francisco
Genentech, Inc.

Completed

The Effect of Rituximab on the Development of Anti-Donor Antibodies

Renal Transplant Rejection

United States
Genentech, Inc.
Seagen Inc.

Completed

A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Terminated

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

Lymphoma | Leukemia | Lymphoproliferative Disorder

United States
University College, London
Roche Pharma AG; Cancer Research UK

Completed

Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Lymphoma

New Zealand, United Kingdom, Australia
BeiGene

Active, not recruiting

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, China, Taiwan, Belgium, France, United Kingdom, Spain, New Zealand, Australia, Czechia, Italy, Poland, Russian Federation, Sweden, Austria
Medical University of Vienna

Completed

A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

Rheumatoid Arthritis

Austria, Czechia, Russian Federation, Switzerland
University of Southampton
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (P+R-ICE)

Diffuse Large B Cell Lymphoma

United Kingdom
GWT-TUD GmbH
Hoffmann-La Roche

Recruiting

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (Pola-R-ICE)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-cell Lymphoma

Germany, Spain, United Kingdom, Austria
Hoffmann-La Roche

Completed

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Italy, Korea, Republic of, Australia, Canada, Czechia, Spain, United Kingdom, France, Germany, Hungary, Turkey, Netherlands
Shoichi Maruyama MD PhD

Recruiting

Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome (PRIME)

Glomerulonephritis, Membranous | Nephrotic Syndrome，Idiopathic

Japan
CHU de Reims

Unknown

Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions (RADIO-LYMPH)

Indolent Cutaneous B Cell Lymphomas

France
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Lymphoma

United States
SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Low-grade B Cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated

Japan
Oslo University Hospital
Norwegian Cancer Society; Helse Sor-Ost

Completed

Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma (Lymvac-1)

Follicular Lymphoma

Norway
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

France, United States, Spain, Korea, Republic of, Australia, Israel, India, Thailand, China, Czech Republic, Belgium, New Zealand, Russian Federation, Finland, South Africa, United Kingdom, Italy, Brazil, Hungary, Puerto Rico, A... and more
Karolinska University Hospital

Completed

Safety and Efficacy Study of Rituximab in Renal Transplantation

Renal Transplantation

Sweden
Lymphoma Study Association

Completed

Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden

Lymphoma

France, Belgium
Shandong University
China Medical University, China; The Affiliated Hospital of the Chinese Academy... and other collaborators

Withdrawn

Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Purpura | Idiopathic Thrombocytopenic Purpura

China
University Hospital, Geneva

Active, not recruiting

A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma (FRILLY)

Aggressive B-Cell Non-Hodgkin Lymphoma

Switzerland
Jean M. Tersak, M.D.
Genentech, Inc.

Terminated

Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

Neuroblastoma | Opsoclonus-myoclonus
Institut fuer anwendungsorientierte Forschung und...
German High-Grade Non-Hodgkin's Lymphoma Study Group; University Hospital Goettingen

Completed

Allo-hNHL (FluBuCy)

Non-Hodgkin's Lymphoma

Germany
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

Pharmacokinetics, Efficacy and Safety of the 304 Injection

CD20 Positive B Cell NHL

China
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)

Rheumatoid Arthritis

Sweden, Canada
Stanford University
Genentech and Biogen IDEC

Completed

Rituximab for Pediatric Renal Transplant Rejection

Kidney Transplantation

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Nagoya University
Japan Agency for Medical Research and Development; Zenyaku Kogyo Co., Ltd.

Completed

The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies (RECIPE)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Japan
Sanofi

Completed

Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Norway, Austria, France
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia
Georg Hess, MD
Roche Pharma AG; Klinikum Frankfurt Höchst

Completed

Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma (Mz-135)

Relapsed Non-Hodgkin-Lymphoma
National Institute of Neurological Disorders and...

Completed

Rituximab to Treat Stiff Person Syndrome

Stiff Person Syndrome

United States
International Extranodal Lymphoma Study Group (IELSG)

Completed

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

Lymphoma, Mucosa-Associated Lymphoid Tissue

United Kingdom, France, Italy, Switzerland, Spain, Belgium
Andres J. M. Ferreri
AGC Biologics S.p.A.

Completed

RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor (INGRID)

Lymphoma, Large B-Cell, Diffuse

Italy
National Cancer Institute (NCI)

Completed

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Terminated

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Post-transplant Lymphoproliferative Disorder | Recurrent Childhood Large Cell Lymphoma | Recurrent Childhood Lymphoblastic Lymphoma | Recurrent Childhood Small Noncleaved Cell Lymphoma | Recurrent/Refractory Childhood Hodgkin Lymphoma | AIDS-related Peripheral/Systemic Lymphoma | AIDS-related...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Aggressive Non-Hodgkin Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Recurrent Non-Hodgkin... and other conditions

United States
Istituto Giannina Gaslini
Bambino Gesù Hospital and Research Institute

Recruiting

Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome. (RTXvsMMF)

Nephrotic Syndrome Steroid-Dependent

Italy
Millennium Pharmaceuticals, Inc.

Completed

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Follicular Lymphoma | B-Cell Lymphoma | Marginal Lymphoma

United States
French National Agency for Research on AIDS and...
Hoffmann-La Roche

Terminated

Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma

AIDS Related Lymphoma

France
San Antonio Military Medical Center

Unknown

Use of Hypertonic Saline After Damage Control Laparotomy to Improve Early Primary Fascial Closure

Open Abdomen After Damage Control Laparotomy

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, United States, Spain, Belgium, Austria, Czechia, Australia, Italy, Japan, Hungary, United Kingdom, Taiwan, Turkey, Germany, Canada, France, Israel, Poland, Croatia, Korea, Republic of, Ireland, Russian Federation, Singapore, Sw...
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, Spain, Czechia, Taiwan, Italy, Japan, New Zealand, Poland, Hungary, United States, United Kingdom, Australia, Romania, Portugal, Korea, Republic of, Russian Federation, Austria, Brazil, Bulgaria, France, Ireland
University Hospital, Rouen

Not yet recruiting

Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus (RITUX4)

Pemphigus | Dermatologic Disease
Byondis B.V.

Recruiting

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

Lymphoma

Spain, United Kingdom, Netherlands, Italy

Search clinical trials for: rituximab [MabThera]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations